US lawmakers questions FDAs drug inspection programme in India and China
Tuesday, 25 June 2024 () Three US lawmakers have raised concerns about the FDA's foreign drug inspection program in India and China, citing inconsistent inspection outcomes. They noted significant variability in findings, suggesting potential issues in inspector competency and thoroughness, and called for further investigation into the program's efficacy and reliability.
Supreme Court Upholds , FDA Regulation on Popular , Abortion Drug Mifepristone.
On June 13, the Supreme Court ruled against a group of
doctors who challenged the Food and Drug Administration's
(FDA) regulations on the abortion pill mifepristone.
CBS reports that the case once again highlighted
abortion access following the conservative
majority decision to overturn Roe v. Wade in 2022.
The court ruled unanimously that the group of
anti-abortion rights doctors and medical associations
lacked the legal right to challenge the FDA. .
However, the court also did not address
whether the FDA's decision to relax the
rules for mifepristone's use were lawful. .
The latest ruling was authored
by Justice Brett Kavanaugh. .
Under Article III of the Constitution,
a plaintiff's desire to make a drug
less available for others does
not establish standing to sue. , Justice Brett Kavanaugh writing for the court, via CBS.
Nor do the plaintiffs' other
standing theories suffice.
Therefore, the plaintiffs lack
standing to challenge FDA's actions, Justice Brett Kavanaugh writing for the court, via CBS.
CBS reports that the ruling does not impact other
challenges to the FDA's standing on mifepristone,
while preserving access to the popular abortion medication.
In 2016 and 2021, the FDA took steps to widen access
to mifepristone, which has been taken by over
5 million patients since first being approved in 2000.
Those steps included allowing the drug to be taken up to 10
weeks into a pregnancy, reducing the number of in-person
doctor visits and permitting it to be sold through the mail.
Credit: Wibbitz Top Stories Duration: 01:30Published
Microdose Chocolate , May Cause Seizures, FDA Warns.
The FDA says that several people in
four states have gotten sick after eating Diamond Shruumz chocolate bars.
Severe symptoms experienced by the victims include "seizures, central nervous system depression, agitation, abnormal heart rates, hyper/hypotension, nausea and vomiting," CBS News reports. .
The chocolate, which is sold across the country, landed six of the eight victims in the hospital. .
The company's website says that the chocolate
is manufactured with a "primo proprietary blend
of nootropic and functional mushrooms.".
In 2022, the FDA called nootropics "a term widely used to market unapproved products as 'smart drugs' and 'cognitive enhancers.'".
On June 7, the FDA warned parents to
keep their kids away from the chocolate
which is marketed as candy. .
Parents and caregivers should consider
discussing the information in this
advisory with their children and take
extra care to avoid this product being
consumed by younger people. , FDA, via statement.
Half of the victims were in
Arizona, CBS News reports. .
While these products claim to
contain only natural ingredients
and no scheduled drugs, there is
clearly something toxic occurring, Steve Dudley, director of the Arizona Poison and
Drug Information Center, via news release.
We've seen the same phenomenon
of people eating the chocolate bar
then seizing, losing consciousness,
and having to be intubated, Steve Dudley, director of the Arizona Poison and
Drug Information Center, via news release
Credit: Wibbitz Top Stories Duration: 01:30Published
FDA Reverses Ban , on Juul E-Cigarettes.
On June 6, the Food and Drug Administration
announced that it has reversed its ban on Juul
e-cigarettes while the agency reviews new information.
On June 6, the Food and Drug Administration
announced that it has reversed its ban on Juul
e-cigarettes while the agency reviews new information.
NBC reports that the FDA first ordered Juul to take its
product off the market in 2022, however the e-cigarettes
have remained on shelves pending the company's appeal.
NBC reports that the FDA first ordered Juul to take its
product off the market in 2022, however the e-cigarettes
have remained on shelves pending the company's appeal.
In that time, Juul has maintained
its position as the second-most
popular e-cigarette in the U.S.
The FDA noted that reversing the ban
temporarily was not an indication that the
company's product would be ultimately cleared. .
The FDA noted that reversing the ban
temporarily was not an indication that the
company's product would be ultimately cleared. .
Sales of alternative nicotine
products, like e-cigarettes, have
continued to grow in the past decade. .
In 2023, the Centers for Disease Control and
Prevention reported that e-cigarette use had
grown by almost 50% between 2020 and 2022. .
In 2023, the Centers for Disease Control and
Prevention reported that e-cigarette use had
grown by almost 50% between 2020 and 2022. .
Juul released a statement
following the FDA reversal, .
... saying the company looks forward to "re-engaging
with the agency on a science- and evidence-based
process to pursue a marketing authorization.".
We remain confident in the quality
and substance of our applications
and believe that a full review of
the science and evidence will
demonstrate that our products
meet the statutory standard
of being appropriate for
the protection of public health, Juul statement, via NBC.
We remain confident in the quality
and substance of our applications
and believe that a full review of
the science and evidence will
demonstrate that our products
meet the statutory standard
of being appropriate for
the protection of public health, Juul statement, via NBC.
'The Wall Street Journal' reports that Juul has argued
that the 2022 ban significantly disrupted the company's
finances, resulting in an investor bailout.
Currently, the FDA has only granted approval for 23
e-cigarette products, manufactured by only three
companies, to be marketed and sold to consumers
Credit: Wibbitz Top Stories Duration: 01:31Published
FDA Reviewing Data on MDMA , for Potential Approval of , Groundbreaking PTSD Treatment.
'The Independent' reports that federal health advisers are
considering a first-ever approval of MDMA, a psychedelic
drug, to treat post traumatic stress disorder (PTSD).
'The Independent' reports that federal health advisers are
considering a first-ever approval of MDMA, a psychedelic
drug, to treat post traumatic stress disorder (PTSD).
The news comes after decades of
psychedelic advocates urging regulators
to give the drug medical acceptance. .
On June 4, the Food and Drug Administration
(FDA) called on a group of outside experts
to review the latest MDMA research. .
The research suggests that when the drug is paired with talk therapy, it can help alleviate PTSD. .
However, regulators at the FDA have questioned the
reliability of the data, as well as the potential safety risks,
which include possible heart problems and addiction.
FDA approval could open the door for federal
approval to be granted as soon as this summer. .
Approval would make MDMA, often referred to as
ecstasy or molly, the first illegal psychedelic
to receive approval for mainstream medicine. .
'The Independent' reports that a number of
psychedelics are expected to receive FDA
reviews in the coming years amid interest in their
potential to treat depression, anxiety and addiction.
'The Independent' reports that a number of
psychedelics are expected to receive FDA
reviews in the coming years amid interest in their
potential to treat depression, anxiety and addiction.
Itβs clear that MDMA-assisted
therapy would be a welcome
addition to the currently
available options, Dr. Kelley O'Donnell, a New York University psychiatrist who
helped conduct the MDMA studies, via 'The Independent'.
Iβve seen firsthand
how this treatment can
be lifesaving for some, Dr. Kelley O'Donnell, a New York University psychiatrist who
helped conduct the MDMA studies, via 'The Independent'
Credit: Wibbitz Top Stories Duration: 01:30Published